United Therapeutics Q1 2021 Earnings Report
Key Takeaways
United Therapeutics reported a 6% year-over-year increase in total revenue, reaching $379.1 million in the first quarter of 2021. The company also saw net income decrease by 79% to $28.3 million, and non-GAAP earnings increased by 2% to $162.1 million.
Total revenue grew 6% year-over-year to $379.1 million.
Net income decreased 79% to $28.3 million.
Non-GAAP earnings increased 2% to $162.1 million.
Tyvaso approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
Forward Guidance
United Therapeutics is focused on obtaining the necessary approvals to launch Tyvaso DPI and the Implantable System for Remodulin, and is progressing with research and development plans related to the PERFECT and TETON studies of Tyvaso, the ADVANCE studies of ralinepag, and organ transplantation programs.
Positive Outlook
- Recent launches of Remunity Pump for Remodulin and Tyvaso for patients with PH-ILD.
- Efforts to obtain approvals to launch Tyvaso DPI.
- Ongoing research and development plans related to the PERFECT and TETON studies of Tyvaso.
- ADVANCE studies of ralinepag.
- Organ transplantation programs.
Challenges Ahead
- Risk that the company will not obtain the necessary FDA approvals to launch the products expected to launch in 2021.
- Uncertainties related to the timing and success of efforts to launch Tyvaso DPI.
- Dependence on Medtronic satisfying various conditions to its PMA approval for Implantable System for Remodulin (ISR).
- Risk that conditions for ISR launch will not be satisfied in time for a 2021 launch.
- The forward-looking statements are subject to certain risks and uncertainties described in periodic reports filed with the Securities and Exchange Commission.
Revenue & Expenses
Visualization of income flow from segment revenue to net income